Urology Times JournalProstate CancerBladder CancerOAB and IncontinenceSUO Annual MeetingAround the Practice: January 2021 Virtual Tumor BoardAUA ConferenceEvolving Treatment ApproachesPerspectives in mCRPCThe Latest in Testosterone Replacement Therapy

BlogsResidents Lounge

Health ITHealth Law & PolicyMalpractice ConsultPersonal FinancePractice Management

All ClinicalBenign ConditionsBenign Prostatic HyperplasiaBladder CancerChallenging AnatomyDrug TherapyFemale UrologyGenitourinary CancersKidney CancerKidney StonesMen's HealthPediatricsProstate CancerSexual DysfunctionUrologic Surgery

Podcasts'Y'tubeK-CastUTv VideosAround the PracticeBPH VideosMedical World NewsReadout 360Viewpoints

Urologists in Cancer CareUrology Times Journal

Live EventsVirtual Events

EducationInteractive ToolsJob BoardSponsored Resources

eNewsletterPrint Subscription

Advertise
Contact Us
Job Board
Terms and Conditions
Privacy
Do not sell my Personnal Information

© 2021 MJH Life Sciences and Urology Times. All rights reserved.

Spotlight

Urology Times Journal
Prostate Cancer
Bladder Cancer
OAB and Incontinence
SUO Annual Meeting
Around the Practice: January 2021 Virtual Tumor Board
AUA Conference
Evolving Treatment Approaches
Perspectives in mCRPC
The Latest in Testosterone Replacement Therapy

Opinion

Blogs
Residents Lounge

BusinessSee All >

Health IT
Health Law & Policy
Malpractice Consult
Personal Finance
Practice Management

Advertise
Contact Us
Job Board
Terms and Conditions
Privacy
Do not sell my Personnal Information

© 2021 MJH Life Sciences^™ and Urology Times. All rights reserved.

VEGF antibody plus chemo shows activity in prostate Ca

March 1, 2004

PSA decline of >50% observed in three-fourths of patients, partialresponse seen in 44%

Related Content: